ABEONA THERAPEUTICS INC. (ABEO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US00289Y2063
ABEONA THERAPEUTICS INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 5.82 m USD |
| Gross profit | 4.29 m USD |
| Operating income | -89.45 m USD |
| EBIT | 75.02 m USD |
| Net income | 71.18 m USD |
| Diluted EPS – continuing operations | 1.01 USD |
Full history since 1995, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ABEONA THERAPEUTICS INC.
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
More stocks
- SHL Consolidated Bhd (6017.KL)
- Hsin Kao Gas Co Ltd (9931.TW)
- Inclusio Sca (INCLU.BR)
- Tander Inversiones SOCIMI SA (YTAN.MC)
- Romerike Sparebank (ROMER.OL)
- Z Squared Inc. (ZSQR)
- Daehan Flour Mills Co Ltd (001130.KS)
- Hoteles City Express S.A.B. de C.V (HCITY.MX)
- St.Shine Optical Co Ltd (1565.TWO)
- Pulmonx Corp (LUNG)
- Soluna Holdings, Inc (SLNH)
- S & Sys Co.,Ltd. (0008Z0.KQ)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.